Company Overview of X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc., a clinical-stage oncology company, develops oral small molecule CXCR4 antagonists for the treatment of refractory solid tumors. It focuses on developing X4P-001, a drug candidate for refractory clear cell renal cell carcinoma and refractory epithelial ovarian cancer; and X4P-002, a series of late lead molecules that penetrate the blood brain barrier. The company was incorporated in 2012 and is based in Cambridge, Massachusetts.
784 Memorial Drive
Cambridge, MA 02139
Founded in 2012
Key Executives for X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc. Key Developments
Similar Private Companies By Industry
|1st Order Pharmaceuticals, Inc.||United States|
|21st Century Animal Health||United States|
|3 Buds' Organics LLC||United States|
|4P Therapeutics LLC||United States|
|60° Pharmaceuticals, LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|NYC2012, Inc.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact X4 Pharmaceuticals Inc., please visit www.x4pharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.